Home › Cardiovascular Disease › South Carolina › Greenville
Cardiovascular Disease clinical trials in Greenville, SC
5 studies for Cardiovascular Disease are looking for participants at sites in and around Greenville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RecruitingPhase 3
- Tribe Clinical Research LLC - Greenville, Greenville
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RecruitingPhase 3
- Clinical Trial Site, Greenville
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RecruitingPhase 3
- Prisma Health Carolina Cardiology - Greenville, Gantt · 4 mi away
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Recruiting
- PRISMA Health- Upstate, Greenville
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
Recruiting
- Prisma Health, Greenville
Cardiovascular Disease trials in other cities
- Boston, MA37 studies
- New York City, NY33 studies
- Washington, DC28 studies
- Houston, TX24 studies
- Dallas, TX23 studies
- Atlanta, GA22 studies
- Cleveland, OH22 studies
- Chicago, IL21 studies
- Philadelphia, PA21 studies
- Pittsburgh, PA20 studies
- St. Louis, MO20 studies
- Nashville, TN18 studies
Other studies in Greenville
- Non-Small Cell Lung Cancer15 studies
- Breast Cancer12 studies
- Acute Myeloid Leukemia10 studies
- Cancer (all types)9 studies
- Obesity9 studies
- Lung Cancer9 studies
- Overweight8 studies
- Prostate Cancer7 studies
- Colorectal Cancer7 studies
- Stomach Cancer6 studies
- Peripheral Arterial Disease5 studies
- Burkitt Lymphoma5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.